MARKET

ACOR

ACOR

Acorda
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.22
-1.56
-23.01%
After Hours: 5.40 +0.18 +3.45% 18:21 03/05 EST
OPEN
5.91
PREV CLOSE
6.78
HIGH
6.20
LOW
4.860
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
9.84
52 WEEK LOW
2.530
MARKET CAP
49.50M
P/E (TTM)
0.9812
1D
5D
1M
3M
1Y
5Y
QIAGEN (QGEN) Unveils Digital Platform for Syndromic Testing
Zacks.com · 1d ago
SIFY, WTI, OPEN and EVFM among notable midday movers
Gainers: Second Sight Medical Products (EYES) +337%.AMTD International (HKIB) +27%.Sify Technologies Limited (SIFY) +26%.Boqii Holding Limited (BQ) +25%.ChromaDex Corporation (CDXC) +22%.W&T Offshore (WTI) +21%.Anchiano Therapeutics (ANCN) +18%.Purple Inno...
Seekingalpha · 2d ago
Friday Sector Laggards: Advertising, Biotechnology Stocks
Mar 05, 2021 (MarketNewsVideo.com via COMTEX) -- In trading on Friday, advertising shares were relative laggards, down on the day by about 6.9%. Helping drag...
MarketNewsVideo.com · 2d ago
Second Sight Medical Products, XTL Biopharmaceuticals leads healthcare gainers; Evofem Biosciences, T2 Biosystems among major losers
Gainers: Second Sight Medical Products (EYES) +151%, XTL Biopharmaceuticals (XTLB) +42%, Nurix Therapeutics (NRIX) +9%, Auris Medical Holding (EARS) +5%, Anchiano Therapeutics (ANCN) +5%.Losers: Evofem Biosciences (EVFM) -34%, T2 Biosystems (TTOO) -25%, IM...
Seekingalpha · 2d ago
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4)
Benzinga · 2d ago
How to trade Acorda Therapeutics $ACOR With Risk Controls
Mar 05, 2021 (Stock Traders Daily via COMTEX) -- Price matters most to making money in the market. Celebrating 20 years, Stock Traders Daily provides the...
Stock Traders Daily · 2d ago
--Analyst Actions: Wedbush Adjusts Price Target on Acorda Therapeutics to $5 From $4, Maintains Neutral Rating
MT Newswires · 2d ago
8-K: ACORDA THERAPEUTICS INC
(EDGAR Online via COMTEX) -- false 0001008848 0001008848 2021-03-04 2021-03-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACOR. Analyze the recent business situations of Acorda through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACOR stock price target is 17.00 with a high estimate of 30.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 221
Institutional Holdings: 5.90M
% Owned: 62.17%
Shares Outstanding: 9.48M
TypeInstitutionsShares
Increased
13
1.04M
New
30
-581.98K
Decreased
15
428.71K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
John Kelley
Chief Executive Officer/President/Director
Ron Cohen
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance/Controller
Robert Morales
Other
Burkhard Blank
Other
Lauren Sabella
Independent Director
Barry Greene
Independent Director
Peder Jensen
Independent Director
Sandra Panem
Independent Director
Lorin Randall
Independent Director
Catherine Strader
No Data
  • All
  • Financials
  • Insiders
More
About ACOR
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Webull offers kinds of Acorda Therapeutics Inc stock information, including NASDAQ:ACOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACOR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACOR stock methods without spending real money on the virtual paper trading platform.